Sterling Technology | Virtual Data Rooms’ Post

Are you ready for a digital-first future in #lifesciences dealmaking? Transactions involving digital assets are an increasing focus for #pharmaceuticals, #medicaldevice and #medtech companies. In our new podcast series, life sciences industry M&A veteran John Easton discusses how these differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks and avoid failure. Technology targets will likely present challenges to dealmakers who are more comfortable evaluating traditional in-licensing or acquisition transactions with pharmaceutical or biotech companies. How should acquirors successfully conduct due diligence on digital assets and what capabilities do they need? To find out, follow the link at the bottom to listen to episode 4 and download the report accompanying the series. Essential information for life sciences dealmakers seeking to navigate an unfamiliar terrain of transactions involving #artificialintelligence, #machinelearning and #bigdata, our five-part series and accompanying report provide insights into differences between digital and traditional deals in key areas including corporate culture, data privacy, intellectual property, asset valuation, due diligence and deal structuring. #mergersacquisitionsdivestitures #corporatefinance #venturecapital #privateequity https://lnkd.in/ePvU58_j

Are you ready for a digital-first future in #lifesciences dealmaking? Transactions involving digital assets are an increasing focus for #pharmaceuticals, #medicaldevice and #medtech companies. In our podcast series, life sciences industry M&A veteran John Easton discusses how these differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks and avoid failure. In previous episodes, we’ve covered key areas of difference between traditional life science transactions and the new world of digital dealmaking including corporate culture, information governance, defining and valuing the asset, and due diligence. In this fifth and final conversation, we pull these strands together and discuss how they influence transaction structure and terms – which both parties must agree on to bring any deal to a successful conclusion. To listen, follow the link at the bottom. You can also download the report accompanying the series. Essential information for life sciences dealmakers seeking to navigate an unfamiliar terrain of transactions involving #artificialintelligence, #machinelearning and #bigdata, our five-part series and accompanying report provide insights into differences between digital and traditional deals in key areas including corporate culture, data privacy, intellectual property, asset valuation, due diligence and deal structuring. #mergersacquisitionsdivestitures #privateequity #venturecapital #corporatefinance https://lnkd.in/eFJsDmw8

What a year for Seuss+! As we wrap up 2023, we are proud to reflect on our journey marked by collaboration and knowledge-sharing. From launching the inspiring 'Cut the Chat' podcast, offering free four-day email courses, to hosting impactful webinars on navigating the evolving landscape of clinical research, it's been a year of enriching dialogues and insights. We are excited about the strides we have made with our biotech, pharma, specialty supplier, and CRO clients. But most of all, we are proud of the progress we've made together in this ever-evolving industry. As we head towards another year, our commitment remains strong - insightful conversations, problem-solving, and continued knowledge sharing. Get to know our leadership team and more in our end-of-year wrap-up article on our website. Let's continue to learn, grow, and create positive impact in life sciences together. [Read the article👈] https://hubs.ly/Q02dsX030 #SeussPlus #YearInReview #KnowledgeSharing #ClinicalResearch #Biotech #Pharma #CRO

I am excited to share Part 2 of my dynamic conversation with Janet J., VP of Global RA at Terumo Blood and Cell Technologies as a guest on the SSI Executive Conversations Podcast. Janet has had an incredible career working at large global companies with a strong diversity of complex medical device products. In Part 2, we discuss developing talent, a growth mindset, and the challenges of managing remote versus hybrid teams. https://lnkd.in/eZ6vqhCa #autonomy #medtech #regulatoryaffairs #leadership #regulatorystrategy #careerpath

Don’t miss the Quality Means Business Founder/CEO Michel E. Moravia, MSE, MBA as he shares his insights on “Design Verification from Initiation to Commercial Launch” alongside top leaders in the MedTech space! A huge thank you to Shurig Solutions, Inc. for hosting this insightful webinar! #QualityMeansBusiness #quality #designverification #regulatory #manufacturing #medicaldevices #validation #combinationproducts

A few weeks ago CEO/Founder Darwin Shurig hosted a webinar featuring some top leaders in the MedTech space, Tanima Ghosh, Justin Bushko, and Michel E. Moravia, MSE, MBA. This webinar was on "Design Verification From Initiation to Commercial Launch". In this short clip, Tanima begins talking about feasibility and some of the key elements when taking a product through the feasibility phase. Click here to view the full webinar, and subscribe to the SSI YouTube channel for more webinar and podcast content! https://lnkd.in/eJj46seK #MedTech #MedicalDevice #Pharma #IndustryInsights #DesignControls #ProductLaunch #ClinicalTrials #DesignVerification #Validation #DesignQuality #TalentManagement #Quality #Regulatory #Manufacturing

Are you ready for a digital-first future in #lifesciences dealmaking? Transactions involving digital assets are an increasing focus for #pharmaceuticals, #medicaldevice and #medtech companies. In our new podcast series, life sciences industry M&A veteran John Easton discusses how these differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks and avoid failure. In this second episode, we consider information governance and data privacy: when life science and technology companies decide to partner, they quickly discover that there is an inherent conflict between the demands of good information governance on the one hand, which requires control processes and regulatory compliance, and innovation on the other, which requires freedom. How should acquirers and targets manage the resulting frictions in navigating digital deals? To listen and download the report accompanying the series, please follow the link at the bottom. Essential information for life sciences dealmakers seeking to navigate an unfamiliar terrain of transactions involving #artificialintelligence, #machinelearning and #bigdata, our five-part series and accompanying report provide insights into differences between digital and traditional deals in key areas including corporate culture, data privacy, intellectual property, asset valuation, due diligence and deal structuring. #mergersacquisitionsdivestitures #corporatefinance #venturecapital #privateequity https://lnkd.in/eu3g_3xk

🎙 Dive into Sterling Technology | Virtual Data Rooms new podcast series with industry veteran John Easton. Discover how digital assets are transforming transactions in Life Science. Gain key insights on deal success and risk mitigation. Don't miss out! 🎙

In the latest episode of the #ParexelBiotech podcast series, “De-Risking Drug Development,” our host, Paul Bridges, and colleagues focus on critical decision points in phases IIb & III that can ultimately determine the success of your product. Join Sangeeta Budhia, Sinan B. Sarac (MD, MSc, PhD), and Amy Pace as they discuss how to accelerate development and opportunities to differentiate your product through innovative and adaptive trial designs. Learn about the importance of integrated evidence planning and the critical role of early value story development alongside target product profile (TPP) planning. Mitigate development risks and stand out among competitors by planning ahead. Listen here: https://lnkd.in/eJburS9a #Biotech #TrialDesign #ClinicalDevelopment

How is AI supporting pharmaceutical manufacturing and supply chain...? Find out in this episode of the EY Health Sciences and Wellness Experience podcast, where host Patrick T. O’Sullivan discusses with J&J how AI is currently being used to support the pharmaceutical manufacturing and supply chain.